Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

帕博西利布 富维斯特朗 医学 依西美坦 来曲唑 芳香化酶抑制剂 阿那曲唑 内科学 肿瘤科 乳腺癌 临床终点 转移性乳腺癌 芳香化酶 妇科 癌症 临床试验 雌激素受体
作者
François‐Clément Bidard,Anne‐Claire Hardy‐Bessard,Florence Dalenc,Thomas Bachelot,Jean‐Yves Pierga,Thibault de la Motte Rouge,Renaud Sabatier,Coraline Dubot,Jean‐Sébastien Frenel,Jean Marc Ferrero,Sylvain Ladoire,Christelle Levy,Marie‐Ange Mouret‐Reynier,Alain Lortholary,Julien Grenier,Camille Chakiba,Laëtitia Stefani,Jérôme Edouard Plaza,Florian Clatot,Luís Teixeira
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:23 (11): 1367-1377 被引量:304
标识
DOI:10.1016/s1470-2045(22)00555-1
摘要

In advanced oestrogen receptor-positive, HER2-negative breast cancer, acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones, which might be sensitive to fulvestrant. The PADA-1 trial aimed to show the efficacy of an early change in therapy on the basis of a rising ESR1 mutation in blood (bESR1mut), while assessing the global safety of combination fulvestrant and palbociclib.We did a randomised, open-label, phase 3 trial in 83 hospitals in France. Women aged at least 18 years with oestrogen receptor-positive, HER2-negative advanced breast cancer and an Eastern Cooperative Oncology Group performance status of 0-2 were recruited and monitored for rising bESR1mut during first-line aromatase inhibitor (2·5 mg letrozole, 1 mg anastrozole, or 25 mg exemestane, orally once per day, taken continuously) and palbociclib (125 mg orally once per day on days 1-21 of a 28-day cycle) therapy. Patients with newly present or increased bESR1mut in circulating tumour DNA and no synchronous disease progression were randomly assigned (1:1) to continue with the same therapy or to switch to fulvestrant (500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1) and palbociclib (dosing unchanged). The randomisation sequence was generated within an interactive web response system using a minimisation method (with an 80% random factor); patients were stratified according to visceral involvement (present or absent) and the time from inclusion to bESR1mut detection (<12 months or ≥12 months). The co-primary endpoints were investigator-assessed progression-free survival from random assignment, analysed in the intention-to-treat population (ie, all randomly assigned patients), and grade 3 or worse haematological adverse events in all patients. The trial is registered with Clinicaltrials.gov (NCT03079011), and is now complete.From March 22, 2017, to Jan 31, 2019, 1017 patients were included, of whom 279 (27%) developed a rising bESR1mut and 172 (17%) were randomly assigned to treatment: 88 to switching to fulvestrant and palbociclib and 84 patients to continuing aromatase inhibitor and palbociclib. At database lock on July 31, 2021, randomly assigned patients had a median follow-up of 35·3 months (IQR 29·2-41·4) from inclusion and 26·0 months (13·8-34·3) from random assignment. Median progression-free survival from random assignment was 11·9 months (95% CI 9·1-13·6) in the fulvestrant and palbociclib group versus 5·7 months (3·9-7·5) in the aromatase inhibitor and palbociclib group (stratified HR 0·61, 0·43-0·86; p=0·0040). The most frequent grade 3 or worse haematological adverse events were neutropenia (715 [70·3%] of 1017 patients), lymphopenia (66 [6·5%]), and thrombocytopenia (20 [2·0%]). The most common grade 3 or worse adverse events in step 2 were neutropenia (35 [41·7%] of 84 patients in the aromatase inhibitor and palbociclib group vs 39 [44·3%] of 88 patients in the fulvestrant and palbociclib group) and lymphopenia (three [3·6%] vs four [4·5%]). 31 (3·1%) patients had grade 3 or worse serious adverse events related to treatment in the overall population. Three (1·7%) of 172 patients randomly assigned had one serious adverse event in step 2: one (1·2%) grade 4 neutropenia and one (1·2%) grade 3 fatigue among 84 patients in the aromatase inhibitor and palbociclib group, and one (1·1%) grade 4 neutropenia among 88 patients in the fulvestrant and palbociclib group. One death by pulmonary embolism in step 1 was declared as being treatment related.PADA-1 is the first prospective randomised trial showing that the early therapeutic targeting of bESR1mut results in significant clinical benefit. Additionally, the original design explored in PADA-1 might help with tackling acquired resistance with new drugs in future trials.Pfizer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
liu完成签到 ,获得积分10
刚刚
刚刚
刚刚
womujk发布了新的文献求助10
刚刚
Akim的应助被AAA采纳,获得10
刚刚
captainHc发布了新的文献求助100
刚刚
李健的应助被dxftx采纳,获得10
1秒前
房子完成签到,获得积分10
2秒前
2秒前
乐乐的应助被sfliufighting采纳,获得10
3秒前
领导范儿的应助被冷冷子采纳,获得80
3秒前
香蕉觅云的应助被EstAffectus采纳,获得30
4秒前
CodeCraft的应助被EstAffectus采纳,获得30
4秒前
李健的应助被EstAffectus采纳,获得10
4秒前
4秒前
桐桐的应助被EstAffectus采纳,获得10
4秒前
NexusExplorer的应助被EstAffectus采纳,获得30
4秒前
搜集达人的应助被EstAffectus采纳,获得10
5秒前
李健的应助被EstAffectus采纳,获得10
5秒前
李爱国的应助被EstAffectus采纳,获得30
5秒前
5秒前
所所的应助被EstAffectus采纳,获得10
5秒前
烟花的应助被EstAffectus采纳,获得10
5秒前
房子发布了新的文献求助10
5秒前
hc发布了新的文献求助10
6秒前
鸽子二号完成签到,获得积分10
6秒前
二二春完成签到,获得积分10
7秒前
深情安青的应助被友好的诗筠采纳,获得10
8秒前
椰椰完成签到,获得积分10
8秒前
8秒前
nami发布了新的文献求助10
8秒前
8秒前
彩色樱桃发布了新的文献求助10
8秒前
大晴子发布了新的文献求助10
9秒前
10秒前
zombie发布了新的文献求助10
11秒前
Maestro_S的应助被EstAffectus采纳,获得150
11秒前
NexusExplorer的应助被EstAffectus采纳,获得10
11秒前
爆米花的应助被EstAffectus采纳,获得30
11秒前
困了发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184508
求助须知:如何正确求助?哪些是违规求助? 9573478
关于积分的说明 21831914
捐赠科研通 7781737
什么是DOI,文献DOI怎么找? 3434372
关于科研通互助平台的介绍 2558482
邀请新用户注册赠送积分活动 2480962